InvestorsHub Logo
Followers 0
Posts 32
Boards Moderated 0
Alias Born 04/08/2014

Re: Vaffan-Coulo post# 11754

Tuesday, 01/20/2015 4:41:43 PM

Tuesday, January 20, 2015 4:41:43 PM

Post# of 15274
None of that is interesting

After two listings of randomized trials that were anything but, an interesting and significant study comes out and you can only find trivial negative things to say?

How about these?

The study was funded and executed by individuals who have nothing to do with the inventor or any company affiliated with the technology

The study had numerous objective end points, including looking for "pain genes" in patients blood serum.

There were numerous other objective end points - like patients response to temperature stimulus.

The study was powered to show a difference in outcomes.

There were statistically better results in treated patients than Sham patients. The benefits were not sham.

One point Mr. swear word in some foreign language makes is that the treatment protocol is not the same as would be taught by the inventor. I agree. But if a clinician followed Marineo's protocol, it would be really hard to complete a sham protocol.

For low back pain, this study as published, the patients did better with a suboptimal treatment than a sham. The objective measurement criteria and the desegregation from a manufacturer are quite unusual and notable.

Mr. Viet Cong (VCs real purpose) analysis are pretty bogus. Doesn't mean Calmare has any future selling this technology. They paid tons of money getting FDA clearance and pursuing US patents. Now the inventor all but owns those things unless CTT is able to settle with the inventor.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.